Back to Journals » Vascular Health and Risk Management » Volume 9

Endoglin: a critical mediator of cardiovascular health

Authors Kapur NK, Morine KJ, Letarte M

Received 11 September 2012

Accepted for publication 9 February 2013

Published 6 May 2013 Volume 2013:9 Pages 195—206


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Navin K Kapur,1 Kevin J Morine,1 Michelle Letarte2,3

1Molecular Cardiology Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA; 2Molecular Structure and Function Program, Hospital for Sick Children, 3The Heart and Stroke Foundation Richard Lewar Centre of Excellence, and the Department of Immunology, University of Toronto, Toronto, Ontario, Canada

Abstract: Endoglin (CD105) is a type III auxiliary receptor for the transforming growth factor beta (TGFß) superfamily. Several lines of evidence suggest that endoglin plays a critical role in maintaining cardiovascular homeostasis. Seemingly disparate disease conditions, including hereditary hemorrhagic telangiectasia, pre-eclampsia, and cardiac fibrosis, have now been associated with endoglin. Given the central role of the TGFß superfamily in multiple disease conditions, this review provides a detailed update on endoglin as an evolving therapeutic target in the management of cardiovascular disease.

Keywords: endoglin, transforming growth factor beta, vascular, cardiac remodeling

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.